Page last updated: 2024-11-05

phenacid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phenacid: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25306
CHEMBL ID518
SCHEMBL ID7468547
MeSH IDM0053015

Synonyms (54)

Synonym
paam
2-(p-(bis(2-chloroethyl)amino)phenyl)acetic acid
(4-(bis(2-chloroethyl)amino)phenyl)acetic acid
cb 1331
4-(bis(2-chloroethyl)amino)benzeneacetic acid
(p-(bis(2-chloroethyl)amino)phenyl)acetic acid
acetic acid, 2-(p-(bis(2-chloroethyl)amino)phenyl)-
phenylacetic mustard
p-(n,n-di(2-chloroethyl)amino)phenylacetic acid
phenylacetic acid mustard
acetic acid, (p-(bis(2-chloroethyl)amino)phenyl)-
brn 0960062
phenacid
benzeneacetic acid, 4-(bis(2-chloroethyl)amino)-
p-n,n-di-(2-chloroethyl)aminophenyl acetic acid
n,n-bis(chloroethyl)-p-aminophenylacetic acid
khlorfenatsil
benzeneacetic acid, 4-[bis(2-chloroethyl)amino]-
acetic acid, [p-[bis(2-chloroethyl)amino]phenyl]-
nsc 71964
10477-72-2
chlorphenacil
2-[p-[bis(2-chloroethyl)amino]phenyl]acetic acid
n,n-bis(2-chloroethyl)-p-aminophenylacetic acid
[p-[bis(2-chloroethyl)amino]phenyl]acetic acid
[4-[bis(2-chloroethyl)amino]phenyl]acetic acid
nsc-71964
chlorphenacyl
nsc71964
p-[n,n-di(2-chloroethyl)amino]phenylacetic acid
p-n,n-(dichloroethyl)aminophenylacetic acid
NCIOPEN2_003741
CHEMBL518
phenylacetic acid mustard (0.25%)
AKOS000588971
2-[4-[bis(2-chloroethyl)amino]phenyl]acetic acid
32842a3uzp ,
4-14-00-01313 (beilstein handbook reference)
unii-32842a3uzp
2-{4-[di(2-chloroethyl)amino]phenyl}acetic acid
p-[di-(2-chloroethyl)amino]phenylacetic acid
RQAFMLCWWGDNLI-UHFFFAOYSA-N
4-[n,n-bis(2-chloroethyl)amino]phenylacetic acid
2-(4-(bis(2-chloroethyl)amino)phenyl)acetic acid
SCHEMBL7468547
bis(2-chloroethyl)aminobenzeneacetic acid, 4-
(p-bis(2-chloroethyl)aminophenyl)acetic acid
DTXSID40146714
SR-01000313749-1
sr-01000313749
4-bis(2-chloroethyl)aminobenzeneacetic acid
Q27256160
HY-136327
CS-0128229

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This different pharmacokinetic behavior might offer an explanation for the superior therapeutic effects of prednimustine demonstrated by clinical studies."( Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.
Loos, U; Malek, M; Mühlenbruch, B; Musch, E; Oppitz, MM; Rüb, HP; von Unruh, GE, 1989
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
"We studied the effects of caffeine alone or in combination with homo-aza-steroidal ester of p-bis(2-chloroethyl)aminophenylacetic acid (ASE, NSC 290205) on the frequency of SCEs and lymphocyte proliferation kinetics."( Synergistic induction of cytogenetic damage by the homo-aza-steroidal ester of p-bis(2-chloroethyl)aminophenylacetic acid in combination with caffeine in human lymphocytes in vitro and in Ehrlich ascites tumour cells in vivo.
Catsoulacos, P; Dozi-Vassiliades, J; Mourelatos, D; Petrou, C, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID382021Acute toxicity in ip dosed BALB/c mouse after 30 days2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.
AID382057Antitumor activity in BDF1 mouse bearing P388 cells assessed as number of cured mouse at 5 mg/kg/day, ip after 90 days2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1132022Antitumor activity against mouse L1210 cells assessed as dose required to produce T/C of 125% administered for 15 days1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships in antitumor aniline mustards.
AID382063Antitumor activity in BDF1 mouse L1210 cells assessed as number of cured mouse at 5 mg/kg/day, ip after 90 days2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.
AID382049Increase in median life span in BDF1 mouse L1210 cells at 5 mg/kg/day, ip relative to corn oil2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.
AID102183Inhibitory concentration was evaluated against colorectal tumar cell line LoVo1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
AID382041Antitumor activity in BDF1 mouse L1210 cells assessed as mean survival days at 5 mg/kg/day, ip2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.
AID1132026Antitumor activity against mouse P388 cells allografted in mouse assessed as dose required to produce T/C of 180% administered for 9 days1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships in antitumor aniline mustards.
AID382033Increase in median life span in BDF1 mouse bearing P388 cells at 5 mg/kg/day, ip relative to corn oil2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1132023Antitumor activity against mouse P388 cells allografted in mouse assessed as dose required to produce T/C of 125% administered for 9 days1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships in antitumor aniline mustards.
AID1132032Stability of the compound in acetone assessed as hydrolysis at 66 degC after 30 mins1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships in antitumor aniline mustards.
AID382025Antitumor activity in BDF1 mouse bearing P388 cells assessed as mean survival days at 5 mg/kg/day, ip2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (57.89)18.7374
1990's5 (26.32)18.2507
2000's3 (15.79)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.93 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]